Gonadorelin
FDA-approved GnRH (diagnostic / historic therapeutic)Established
Native GnRH decapeptide used as a diagnostic and, historically, pulsatile therapeutic. WADA prohibits GnRH and analogues (S2).
For research use only.
Key Facts
- CAS
- 33515-09-2
- Molecular Weight (MW)
- 1182.3 g/mol
- Half-life
- 2–10 minutes
- Unit
- mcg
- Administration Route
- Intravenous / Subcutaneous
- Frequency
- Pulsatile when used therapeutically
- Last updated
- 8/23/2026
- Targets
- GnRH receptor
Overview
Native GnRH decapeptide used as a diagnostic and, historically, pulsatile therapeutic. WADA prohibits GnRH and analogues (S2).
Protocol
- Dosage Range
- Diagnostic and pulsatile regimens per historical labels
- Frequency
- Pulsatile when used therapeutically
- Cycle
- —
- Administration Route
- Intravenous / Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Pulsatile GnRH stimulates LH/FSH; continuous exposure downregulates the axis. Distinct from long-acting agonists like leuprolide.
Targets
GnRH receptor
Studies
- Pulsatile GnRH therapy— Journal/year not available
Benefits
Reproductive-axis diagnostic / pulsatile research
Potential Side Effects
- Ovarian hyperstimulation risk
- Injection reactions
References
- WADA Prohibited List 2026External link · Year —